Eamon Toye
Overview
Explore the profile of Eamon Toye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hwang J, Likasitwatanakul P, Deshmukh S, Wu S, Kwon J, Toye E, et al.
Clin Cancer Res
. 2025 Jan;
31(5):936-948.
PMID: 39745364
Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain...
2.
Miller C, Likasitwatanakul P, Toye E, Hwang J, Antonarakis E
Expert Rev Anticancer Ther
. 2024 Sep;
24(11):1085-1100.
PMID: 39275993
Introduction: Prostate cancer continues to be a major cause of morbidity and mortality for men worldwide. Enzalutamide, a second-generation non-steroidal antiandrogen that blocks androgen receptor (AR) transcriptional activity, is a...
3.
Bergom H, Boytim E, McSweeney S, Sadeghipour N, Elliott A, Passow R, et al.
JCI Insight
. 2024 Aug;
9(20).
PMID: 39207857
BACKGROUNDProstate cancer (PC) is driven by aberrant signaling of the androgen receptor (AR) or its ligands, and androgen deprivation therapies (ADTs) are a cornerstone of treatment. ADT responsiveness may be...
4.
Toye E, Chehrazi-Raffle A, Hwang J, Antonarakis E
Oncotarget
. 2024 Jul;
15:486-492.
PMID: 39018217
Activating mutations in the mitogen-activated protein kinase (MAPK) pathway represent driver alterations governing tumorigenesis, metastasis, and therapy resistance. MAPK activation predominantly occurs through genomic alterations in and . BRAF is...
5.
Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock A, Bergom H, et al.
Clin Cancer Res
. 2023 Jul;
29(19):3948-3957.
PMID: 37477913
Purpose: Alterations in BRAF have been reported in 3% to 5% of prostate cancer, although further characterization is lacking. Here, we describe the nature of BRAF alterations in prostate cancer...
6.
Hwang J, Shi X, Elliott A, Arnoff T, McGrath J, Xiu J, et al.
Clin Cancer Res
. 2023 May;
29(14):2702-2713.
PMID: 37126020
Purpose: In patients with metastatic prostate cancer (mPC), ATM and BRCA2 mutations dictate differences in PARPi inhibitor response and other therapies. We interrogated the molecular features of ATM- and BRCA2-mutated...